In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear attacks. In Renewing the Project BioShield Act: What Has It Bought and Wrought?, Dr. Robert Kadlec, a consultant with RPK Consulting, writes that Project BioShield has achieved its strategic objectives and merits continued support and funding. He argues that the president and Congress should affirm its value as a critical insurance policy against the risk of these types of attacks.
- Women in National Security: Alina Polyakova
Women in National Security: Julie Smith, Loren DeJonge Schulman & Kate Kidder
By Julianne Smith, Loren DeJonge Schulman & Katherine Kidder
Women in National Security: Alice Hunt Friend
By Loren DeJonge Schulman & Alice Hunt Friend
Russia Loves a Shunned U.S. Soldier
By Andrew Swick